Case todayNot read todayThesis-Break EngineThe case · mixed · Oct 13, 2026Own SINT if SINT is a financing-constrained option on whether its silicon nitride ceramics can move from technical promise to repeat commercial adoption.5 conditions2 holding · 3 weakeningNext resultsNot scheduledNo date filed yet

SINT at a glance

The past year

Chart

−57.5% $1.34, close Nov 16

From the highest close
−68.5%
Vs the 200-day average
−36.9%
Nov 14, 2025Daily close, Sintx TechnologiesNov 16, 2026

Short interest

History

128,437 shares

Of shares outstanding
1.70%
Since the last report
−5.9%
Days to cover
7.3 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 10 – Nov 16

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

SINT price history

Latest price$1.34Today−$0.01 (-1.11%)
SINT -21.18%S&P 500 -3.79%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • OEM qualification of SINT’s silicon nitride platform must convert niche technical interest into repeat commercial orders rather than one-off development work.WeakeningMateriality: High

    SINT reported GAAP annual revenue in each year from FY2022 through FY2025, showing some level of commercial activity. If customers qualify the material, revenue can scale from a tiny base; if they do not, the company remains dependent on external financing.

    Watch: Medical device OEMs such as Medtronic, Stryker, or Zimmer Biomet continue standardizing on titanium, PEEK, alumina, or zirconia rather than qualifying silicon nitride.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    SINT reported GAAP annual revenue in each year from FY2022 through FY2025, showing some level of commercial activity.

    Open source ↗
  • SINT’s materials must remain differentiated enough to earn high-value specialty-ceramics economics, not commodity contract-manufacturing economics.HoldingMateriality: High

    FY2025 GAAP annual gross_profit was positive at $461,000 despite the small revenue base. Gross margin determines whether commercialization can fund the platform or merely adds low-quality volume.

    Watch: Incumbent ceramic suppliers match the required specifications and force SINT to compete mainly on price.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 GAAP annual gross_profit was positive at $461,000 despite the small revenue base.

    Open source ↗
  • The operating platform has to be leveraged by commercial volume or structurally reduced; otherwise SINT’s development and manufacturing capabilities consume more cash than they can generate.WeakeningMateriality: Medium

    FY2025 GAAP annual operating_income improved to a loss of $10.721 million from a loss of $14.047 million in FY2024. Operating leverage is the difference between a scalable materials platform and a perpetual loss-making lab.

    Watch: Commercialization requires higher sales, quality-system, regulatory, or manufacturing spending before revenue scales.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 GAAP annual operating_income improved to a loss of $10.721 million from a loss of $14.047 million in FY2024.

    Open source ↗
  • SINT needs strategic funding, non-dilutive capital, or a rapid commercial inflection before cash burn forces financing on terms that dilute existing owners’ upside.WeakeningMateriality: Medium

    Cash was $4.140 million at December 31, 2025, up from $3.598 million at December 31, 2024. Even if the technology eventually works, the stock may not work if shareholders are diluted before adoption arrives.

    Watch: Capital markets become unavailable or punitive for small, loss-making Nasdaq medical-technology issuers.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $4.140 million at December 31, 2025, up from $3.598 million at December 31, 2024.

    Open source ↗
  • A 32-person company must win through focused partnerships and a narrow set of high-probability applications, not by trying to commercialize every possible silicon nitride use case internally.HoldingMateriality: Medium

    SINT had 32 employees as of December 31, 2025. Focus can conserve cash and raise the odds of a fundable win; dispersion increases the risk that no application reaches scale in time.

    Watch: Loss of key technical, manufacturing, regulatory, or business-development personnel slows customer qualification.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    SINT had 32 employees as of December 31, 2025.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

OEM qualification of SINT’s silicon nitride platform must convert niche technical interest into repeat commercial orders rather than one-off development work. If customers qualify the material, revenue can scale from a tiny base; if they do not, the company remains dependent on external financing.

SINT’s materials must remain differentiated enough to earn high-value specialty-ceramics economics, not commodity contract-manufacturing economics. Gross margin determines whether commercialization can fund the platform or merely adds low-quality volume.

The operating platform has to be leveraged by commercial volume or structurally reduced; otherwise SINT’s development and manufacturing capabilities consume more cash than they can generate. Operating leverage is the difference between a scalable materials platform and a perpetual loss-making lab.

SINT needs strategic funding, non-dilutive capital, or a rapid commercial inflection before cash burn forces financing on terms that dilute existing owners’ upside. Even if the technology eventually works, the stock may not work if shareholders are diluted before adoption arrives.

A 32-person company must win through focused partnerships and a narrow set of high-probability applications, not by trying to commercialize every possible silicon nitride use case internally. Focus can conserve cash and raise the odds of a fundable win; dispersion increases the risk that no application reaches scale in time.

All standing thesis claims
Original report summary

SINT is a financing-constrained option on whether its silicon nitride ceramics can move from technical promise to repeat commercial adoption.

Evidence assessed Oct 13, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Sintx Technologies

Where the evidence on Sintx Technologies disagrees: Mixed on the latest evidence (Oct 13, 2026). Of its 5 thesis points, 2 holding and 3 weakening.

Bull case: what the evidence supports

  • SINT’s materials must remain differentiated enough to earn high-value specialty-ceramics economics, not commodity contract-manufacturing economics.

    sec.gov ↗

  • A 32-person company must win through focused partnerships and a narrow set of high-probability applications, not by trying to commercialize every possible silicon nitride use case internally.

    sec.gov ↗

Bear case: what the evidence questions

  • OEM qualification of SINT’s silicon nitride platform must convert niche technical interest into repeat commercial orders rather than one-off development work.

    sec.gov ↗

  • The operating platform has to be leveraged by commercial volume or structurally reduced; otherwise SINT’s development and manufacturing capabilities consume more cash than they can generate.

    sec.gov ↗

  • SINT needs strategic funding, non-dilutive capital, or a rapid commercial inflection before cash burn forces financing on terms that dilute existing owners’ upside.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Sintx Technologies

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Sintx Technologies’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Other material event.

    Sintx Technologies filed an SEC 8-K on 2026-10-09: Other material event. It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    Sintx Technologies filed an SEC 8-K on 2026-10-01: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Regulation FD disclosure.

    Sintx Technologies filed an SEC 8-K on 2026-08-13: Regulation FD disclosure. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Medical device OEMs such as Medtronic, Stryker, or Zimmer Biomet continue standardizing on titanium, PEEK, alumina, or zirconia rather than qualifying silicon nitride.
  • Incumbent ceramic suppliers match the required specifications and force SINT to compete mainly on price.
  • Commercialization requires higher sales, quality-system, regulatory, or manufacturing spending before revenue scales.
  • Capital markets become unavailable or punitive for small, loss-making Nasdaq medical-technology issuers.
  • Loss of key technical, manufacturing, regulatory, or business-development personnel slows customer qualification.

SINT news

Loading headlines…

Financial statements

SINT income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

SINT: quick answers

What is SINT's short interest?
As of October 30, 2026, 128,437 SINT shares were sold short, 1.70% of its shares outstanding, down 5.9% from the count before. At the stock's average daily volume that is 7.3 days to cover. FINRA publishes the count twice a month. SINT short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.